Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DHFR | P00374 | 1/20 | 1.00 |
| ▸ | LMNA | P02545 | 1/20 | 0.79 |
| ▸ | MTHFD1 | P11586 | 2/20 | 0.71 |
| ▸ | SOST | Q9BQB4 | 1/20 | 0.67 |
| ▸ | MTHFD2 | P13995 | 2/20 | 0.62 |
| ▸ | FPGS | Q05932 | 2/20 | 0.60 |
| ▸ | TYMS | P04818 | 1/20 | 0.55 |
| ▸ | GART | P22102 | 5/20 | 0.55 |
| ▸ | ATIC | P31939 | 3/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Leucovorin SCHEMBL159828 | 1.00 | DHFR (1.00) | DHFRLMNAMTHFD1SOSTMTHFD2 | |
| Leucovorin SCHEMBL258832 | 1.00 | DHFR (1.00) | DHFRLMNAMTHFD1SOSTMTHFD2 | |
| Levoleucovorin SCHEMBL639769 | 1.00 | DHFR (1.00) | DHFRLMNAMTHFD1SOSTMTHFD2 | |
| Leucovorin SCHEMBL3031362 | 1.00 | DHFR (1.00) | DHFRLMNAMTHFD1SOSTMTHFD2 | |
| Folinic Acid SCHEMBL29616563 | 1.00 | DHFR (1.00) | DHFRLMNAMTHFD1SOSTMTHFD2 | |
| Leucovorin SCHEMBL29385578 | 1.00 | DHFR (1.00) | DHFRLMNAMTHFD1SOSTMTHFD2 | |
| Leucovorin SCHEMBL29379632 | 1.00 | DHFR (1.00) | DHFRLMNAMTHFD1SOSTMTHFD2 | |
| Leucovorin SCHEMBL36113 | 1.00 | DHFR (1.00) | DHFRLMNAMTHFD1SOSTMTHFD2 | |
| Folinic Acid SCHEMBL21498299 | 1.00 | DHFR (1.00) | DHFRLMNAMTHFD1SOSTMTHFD2 | |
| Leucovorin SCHEMBL4744838 | 0.99 | DHFR (0.98) | DHFRLMNAMTHFD1SOSTMTHFD2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 366 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3841097-B1 | 2,6-BIS(((1H-BENZO[D]IMIDAZOL-2-YL)THIO)METHYL)PYRIDINE AND N2,N6-DIBENZYLPYRIDINE-2,6-DICARBOXAMIDE DERIVATIVES AND RELATED COMPOUNDS AS PHOSPHOINOSITIDE 3-KINASE (PI3K) INHIBITORS FOR TREATING CANCER | BIOMEDICAL RES FOUNDATION OF THE ACADEMY OF ATHENS BRFAA (GR) | 2026-05-20 | — | — | EP | claimed |
| CN-122005500-A | Platinum folinate protein nanoparticle and preparation method and application thereof | 苏州大学 | 2026-05-12 | — | — | CN | claimed |
| EP-3645742-B1 | ANTI-ROR1 ANTIBODIES AND METHODS OF MAKING AND USING THEREOF | SYSTIMMUNE INC (US) | 2026-04-29 | — | — | EP | claimed |
| EP-3781713-B1 | SYSTEMS AND METHODS FOR DETECTING CANCER VIA CFDNA SCREENING | MEMORIAL SLOAN KETTERING CANCER CENTER (US) | 2026-03-18 | — | — | EP | claimed |
| EP-4034169-B1 | THERAPEUTIC DENDRIMER | STARPHARMA PTY LTD (AU) | 2026-02-11 | — | — | EP | claimed |
| EP-3679924-B1 | FORMULATION COMPRISING PARTICLES | WOERWAG PHARMA GMBH & CO KG (DE) | 2025-12-17 | — | — | EP | claimed |
| EP-3212228-B1 | MARAVIROC ALONE OR IN COMBINATION THERAPY FOR THE TREATMENT OF CANCER | UNIV HEIDELBERG RUPRECHT KARLS (DE) | 2025-12-03 | — | — | EP | claimed |
| EP-3806898-B1 | GREMLIN-1 ANTAGONIST FOR USE IN THE TREATMENT OF CANCER | UCB Biopharma SRL (BE) | 2025-10-08 | — | — | EP | claimed |
| EP-3965808-B1 | USE OF PARASITES AND EXTRACELLULAR VESICLES OBTAINED FROM PARASITES IN CANCER TREATMENT | UNIV YEDITEPE (TR) | 2025-09-03 | — | — | EP | claimed |
| EP-3719018-B1 | PURINE AND DEAZAPURINE DERIVATIVES AS PHARMACEUTICAL COMPOUNDS | ASTEX THERAPEUTICS LTD (GB) | 2025-08-27 | — | — | EP | claimed |
| EP-3463345-B1 | PHARMACEUTICAL COMBINATIONS | ARRAY BIOPHARMA INC (US) | 2022-11-02 | — | — | EP | claimed |
| EP-3337456-B1 | LIPOSOMES WITH GINSENOSIDE AS MEMBRANE MATERIAL AND PREPARATIONS AND USE THEREOF | SHANGHAI GINPOSOME PHARMATECH CO LTD (CN) | 2022-10-26 | — | — | EP | claimed |
| EP-2958945-B1 | COMBINATION THERAPY INVOLVING ANTIBODIES AGAINST CLAUDIN 18.2 FOR TREATMENT OF CANCER | ASTELLAS PHARMA INC (JP) | 2022-10-19 | — | — | EP | claimed |
| CN-112691107-B | Pharmaceutical composition and application thereof | 北京斯利安药业有限公司 | 2022-09-02 | — | — | CN | claimed |
| EP-3725810-B1 | COMBINATION THERAPY INVOLVING ANTIBODIES AGAINST CLAUDIN 18.2 FOR TREATMENT OF CANCER | ASTELLAS PHARMA INC (JP) | 2022-07-06 | — | — | EP | claimed |
| EP-2773355-B1 | METHODS, FORMULATIONS, AND KITS FOR RAPIDLY REPLETING FOLATE LEVELS IN WOMEN | SOUTH ALABAMA MEDICAL SCIENCE FOUND (US) | 2022-06-08 | — | — | EP | claimed |
| EP-3319965-B1 | NOVEL COMPOUNDS FOR USE IN TREATING OR PREVENTING CANCEROUS DISEASES | BIOMEDICAL RES FOUNDATION OF THE ACADEMY OF ATHENS (GR) | 2022-05-04 | — | — | EP | claimed |
| EP-3218007-B1 | METHODS AND PHARMACEUTICAL COMPOSITIONS FOR THE TREATMENT OF CANCER | INST NAT SANTE RECH MED (FR) | 2022-04-06 | — | — | EP | claimed |
| CN-113993890-A | anti-CD 73, anti-PD-L1 antibodies and chemotherapy for the treatment of tumors | 免疫医疗有限责任公司 | 2022-01-28 | — | — | CN | claimed |
| EP-3778868-B1 | CELL CULTURE MEDIUM FOR CULTIVATING CELLS, METHOD FOR CULTURING CELLS AND METHOD FOR EXPRESSING AT LEAST ONE RECOMBINANT PROTEIN IN A CELL CULTURE | UGA BIOPHARMA GMBH (DE) | 2022-01-26 | — | — | EP | claimed |